EyePoint Pharmaceuticals

Press Releases

pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information
Sep 17, 2009
pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 17, 2009-- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), (FF:PV3), a leading drug delivery company, today announced that its financial results for the
pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference
Sep 09, 2009
pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference BOSTON --(BUSINESS WIRE)--Sep. 9, 2009-- pSivida Corp , (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care
Two Newly-Published Scientific Papers Showed That the Steroid Used in Company's Iluvien Device Acted as Both a VEGF Inhibitor and Neuroprotectant
Jun 15, 2009
Potential Additional Eye Disease Treatment Applications for the Company's Iluvien Product
pSivida Corp. Reports Results for the Quarter ended March 31, 2009
May 14, 2009
pSivida Corp. Reports Results for the Quarter ended March 31, 2009 WATERTOWN, MA – May 14, 2009 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with the only two ophthalmic sustained delivery products approved by the FDA for treatment of back of the eye diseases, today
pSivida technology featured in multiple abstracts at ARVO Meeting in Florida
Apr 24, 2009
Highlights Emerging Technologies and Clinical Data on New and Existing Products
pSivida's Iluvien Phase III Study passes final DSMB Review
Apr 09, 2009
pSivida's Iluvien Phase III Study passes final DSMB Review Watertown, MA. (April 9, 2009) – pSivida Corp. (NASDAQ:PSDV, ASX:PVA, FF:PV3), a leading drug delivery company, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase III
pSivida CEO to Present at IBC Ocular Angiogenesis Conference
Mar 30, 2009
pSivida CEO to Present at IBC Ocular Angiogenesis Conference Boston, MA (March 30, 2009) – pSivida Corp., (NASDAQ:PSDV, ASX:PSD, FF:PV3), a leading drug delivery company, today announced that Dr. Paul Ashton, President and Chief Executive Officer, will make a presentation on ocular drug delivery
Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study
Mar 13, 2009
Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study Watertown, MA - March 13, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic
pSivida to Present at Cowen Health Care Conference in Boston
Mar 12, 2009
pSivida to Present at Cowen Health Care Conference in Boston BOSTON--(Business Wire)-- pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Cowen & Company Annual Health Care Conference in Boston, March 16. Dr.
Enrollment complete in BrachySil Dose Ranging Study
Mar 05, 2009
Enrollment complete in BrachySil Dose Ranging Study Watertown, MA – March 5, 2009 – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced the completion of enrollment of the BrachySil™ (P32 BioSilicon™) dose ranging clinical trial.
Feb 12, 2009
Feb 12, 2009
Dr. Paul Ashton appointed President and CEO
Feb 03, 2009
Dr. Paul Ashton appointed President and CEO Watertown, MA – February 3, 2009 – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced that Paul Ashton, Ph.D. has been named President and Chief Executive Officer. Dr. David J.
pSivida New Evaluation for Cardiovascular Drug Delivery
Dec 17, 2008
pSivida New Evaluation for Cardiovascular Drug Delivery Watertown, MA (December 16, 2008) - Drug delivery company pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3) has entered into a technology evaluation agreement to evaluate cardiovascular delivery of drugs using pSivida's drug delivery
pSivida new clinical trial for drug delivery device in AMD
Dec 12, 2008
pSivida new clinical trial for drug delivery device in AMD Watertown, MA (December 12, 2008) – Drug delivery company pSivida Corp (NASDAQ: PSDV, ASX: PVA, FF: PV3) today announced that a clinical trial has begun using its MedidurTM delivery technology to treat a form of dry-Age related Macular
pSivida’s BrachySil pancreatic cancer treatment featured on the BBC
Dec 03, 2008
pSivida’s BrachySil pancreatic cancer treatment featured on the BBC Watertown, MA (December 3, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its lead oncology product, BrachySilTM for the treatment of pancreatic cancer, has been featured in a
Nov 21, 2008
Nov 12, 2008
pSivida Corp. September Qtr 2008 Earnings Report
Oct 31, 2008
pSivida Corp. September Qtr 2008 Earnings Report WATERTOWN, MA – October 31, 2008 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its financial results for the first quarter ended September 30, 2008 will be filed with the SEC and the ASX on or
Results from the six-month interim readout of the Human PK Iluvien Study
Oct 02, 2008
Results from the six-month interim readout of the Human PK Iluvien Study Boston, MA – Drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), together with its licensing and development partner, Alimera Sciences have today reported the interim six-month safety and efficacy results
Displaying 361 - 380 of 414
EyePoint Pharmaceuticals